POTENTIALS FOR THE USE OF ANGIOTENSIN II RECEPTOR BLOCKERS IN THE METABOLIC SYNDROME AND ARTERIAL HYPERTENSION


S.V. Nedogoda, T.A. Chalyabi, A.S. Salasyuk, I.N. Barykina. D.A.Pocheptsov, A.A. Ledyaeva, V.V. Tsoma, E.V. Chumachek

SBEI HPE "Volgograd State Medical University", Volgograd
Angiotensin II receptor blockers are considered as one of the three major classes of antihypertensive drugs in the treatment of arterial hypertension in patients with metabolic syndrome. Each representative of this group (losartan, valsartan, candesartan, irbesartan, telmisartan) has clinical and pharmacological features and nuances of clinical applications. Based on their analysis, the algorithm of differential selection of a specific drug is presented.

About the Autors


Nedogoda Sergey Vladimirovich – Head of the Department of Therapy and Endocrinology DIF, MD, Professor, Vice President for Clinical Work SBEI HPE "Volgograd State Medical University". e-mail: nedogodasv@rambler.ru
Chalyabi Tatyana Azizovna – Teaching Assistant at the Department of Therapy and Endocrinology DIF, Ph.D. in Medical Sciences
Chumachek Elena Valeryevna - postgraduate student at the Department of Therapy and Endocrinology DIF, e-mail: elena-chumachek@yandex.ru
Ledyaeva Alla Aleksandrovna - Teaching Assistant at the Department of Therapy and Endocrinology DIF, e-mail: ledy-alla@yandex.ru
Barykina Irina Nikolayevna - Teaching Assistant at the Department of Therapy and Endocrinology DIF, Ph.D. in Medical Sciences
Pocheptsov Dmitry Aleksandrovich - postgraduate student at the Department of Therapy and Endocrinology DIF
Tsoma V.V. - Teaching Assistant at the Department of Therapy and Endocrinology DIF, Ph.D. in Medical Sciences, e-mail: veratsoma1@rambler.ru
Salasyuk Alla Sergeevna - postgraduate student at the Department of Therapy and Endocrinology DIF, e-mail: market32@yandex.ru


Similar Articles


Бионика Медиа